JP2019108336A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019108336A5 JP2019108336A5 JP2019019345A JP2019019345A JP2019108336A5 JP 2019108336 A5 JP2019108336 A5 JP 2019108336A5 JP 2019019345 A JP2019019345 A JP 2019019345A JP 2019019345 A JP2019019345 A JP 2019019345A JP 2019108336 A5 JP2019108336 A5 JP 2019108336A5
- Authority
- JP
- Japan
- Prior art keywords
- weight
- methyloxime
- pyrrolidin
- biphenyl
- hydroxymethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 13
- OLUJSZLBWZWGJT-KOXKPCSVSA-N [(2s,4e)-2-(hydroxymethyl)-4-methoxyiminopyrrolidin-1-yl]-[4-(2-methylphenyl)phenyl]methanone Chemical compound C1C(=N/OC)/C[C@@H](CO)N1C(=O)C1=CC=C(C=2C(=CC=CC=2)C)C=C1 OLUJSZLBWZWGJT-KOXKPCSVSA-N 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 8
- 239000007919 dispersible tablet Substances 0.000 claims 6
- 239000008187 granular material Substances 0.000 claims 6
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 6
- GNWCZBXSKIIURR-UHFFFAOYSA-N (2-docosanoyloxy-3-hydroxypropyl) docosanoate Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCCCCCCCCCCCCCC GNWCZBXSKIIURR-UHFFFAOYSA-N 0.000 claims 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 4
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims 3
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 3
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 claims 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 3
- 239000000378 calcium silicate Substances 0.000 claims 3
- 229910052918 calcium silicate Inorganic materials 0.000 claims 3
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 claims 3
- 229960001681 croscarmellose sodium Drugs 0.000 claims 3
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 3
- 229960001021 lactose monohydrate Drugs 0.000 claims 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 3
- 229920001993 poloxamer 188 Polymers 0.000 claims 3
- 229940044519 poloxamer 188 Drugs 0.000 claims 3
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 claims 3
- 238000005550 wet granulation Methods 0.000 claims 3
- 238000007873 sieving Methods 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 1
- 238000001291 vacuum drying Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13197606.0 | 2013-12-17 | ||
| EP13197606.0A EP2886107A1 (en) | 2013-12-17 | 2013-12-17 | Oral formulations of pyrrolydine derivatives |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016534249A Division JP6479800B2 (ja) | 2013-12-17 | 2014-12-15 | ピロリジン誘導体の経口製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019108336A JP2019108336A (ja) | 2019-07-04 |
| JP2019108336A5 true JP2019108336A5 (OSRAM) | 2019-08-15 |
Family
ID=49765403
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016534249A Active JP6479800B2 (ja) | 2013-12-17 | 2014-12-15 | ピロリジン誘導体の経口製剤 |
| JP2019019345A Pending JP2019108336A (ja) | 2013-12-17 | 2019-02-06 | ピロリジン誘導体の経口製剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016534249A Active JP6479800B2 (ja) | 2013-12-17 | 2014-12-15 | ピロリジン誘導体の経口製剤 |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US20170065556A1 (OSRAM) |
| EP (4) | EP2886107A1 (OSRAM) |
| JP (2) | JP6479800B2 (OSRAM) |
| KR (1) | KR102350156B1 (OSRAM) |
| CN (2) | CN110960495B (OSRAM) |
| AU (1) | AU2014364962B2 (OSRAM) |
| CA (1) | CA2931592C (OSRAM) |
| CY (1) | CY1119728T1 (OSRAM) |
| DK (1) | DK3082773T3 (OSRAM) |
| EA (2) | EA031530B1 (OSRAM) |
| ES (2) | ES2654927T3 (OSRAM) |
| HK (1) | HK1249050B (OSRAM) |
| HU (1) | HUE035212T2 (OSRAM) |
| IL (2) | IL245855B (OSRAM) |
| MX (2) | MX363697B (OSRAM) |
| PT (1) | PT3082773T (OSRAM) |
| SI (1) | SI3082773T1 (OSRAM) |
| UA (1) | UA116824C2 (OSRAM) |
| WO (1) | WO2015091365A1 (OSRAM) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2845850A1 (en) | 2013-09-10 | 2015-03-11 | ObsEva S.A. | Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists |
| EP2886107A1 (en) * | 2013-12-17 | 2015-06-24 | ObsEva S.A. | Oral formulations of pyrrolydine derivatives |
| EP3753921A1 (en) | 2014-07-02 | 2020-12-23 | ObsEva S.A. | Crystalline (3z,5s)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one o-methyloxime useful in methods of treating conditions related to the ot-r activity |
| TWI829098B (zh) | 2015-01-02 | 2024-01-11 | 美商梅拉洛伊卡公司 | 細菌組成物 |
| ES2915948T3 (es) | 2016-01-04 | 2022-06-27 | ObsEva SA | Administración conjunta de alfa-aminoéster de derivado de hidroxipropiltiazolidin-carboxamida y un agente tocolítico |
| WO2018015497A2 (en) * | 2016-07-21 | 2018-01-25 | ObsEva S.A. | Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage |
| IT201600101413A1 (it) | 2016-10-10 | 2018-04-10 | Sofar Swiss S A | Composizione liquida per uso nel trattamento del reflusso gastroesofageo |
| IT201700124434A1 (it) * | 2017-10-31 | 2019-05-01 | Sofar Swiss Sa | Compressa da succhiare e/o sciogliere in bocca a base di acido ialuronico e condroitina solfato e loro sali per uso nel trattamento di una sottopopolazione di pazienti GERD. |
| IT201700124424A1 (it) | 2017-10-31 | 2019-05-01 | Sofar Swiss Sa | Compressa da succhiare e/o sciogliere in bocca a base di acido ialuronico e condroitina solfato e loro sali |
| GB201910125D0 (en) * | 2019-07-15 | 2019-08-28 | Kalvista Pharmaceuticals Ltd | Treatments of angioedema |
| GB201910116D0 (en) * | 2019-07-15 | 2019-08-28 | Kalvista Pharmaceuticals Ltd | Treatments of hereditary angioedema |
| EP4025207A1 (en) * | 2019-09-03 | 2022-07-13 | ObsEva S.A. | Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage |
| AU2021218895A1 (en) | 2020-02-10 | 2022-09-15 | ObsEva S.A. | Biomarkers for oxytocin receptor antagonist therapy |
| SMT202200411T1 (it) | 2020-05-18 | 2022-11-18 | Orexo Ab | Nuova composizione farmaceutica per il rilascio controllato di farmaci |
| AU2022395920A1 (en) | 2021-11-25 | 2024-05-30 | Orexo Ab | Pharmaceutical composition comprising adrenaline |
| GB202117016D0 (en) | 2021-11-25 | 2022-01-12 | Orexo Ab | New pharmaceutical device |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3482815A (en) | 1967-07-07 | 1969-12-09 | Victor Naturale | Collapsible core for a mold |
| YU120988A (en) * | 1988-06-23 | 1990-06-30 | Lek Tovarna Farmacevtskih | Process for preparing new dispersion pills of cimetidine |
| US4832307A (en) | 1988-09-15 | 1989-05-23 | Toshiba Kikai Kabushiki Kaisha | Injection mold |
| YU183988A (en) * | 1988-09-30 | 1990-08-31 | Lek Tovarna Farmacevtskih | Process for preparing dispersion pills of dihydroergotoxine |
| US5089043A (en) | 1989-11-09 | 1992-02-18 | Shionogi & Co., Ltd. | Heterocyclic oxy-phenoxyacetic acid derivatives and their use as herbicides |
| US5889001A (en) | 1993-07-29 | 1999-03-30 | American Cyanamid Company | Tricyclic diazepine vasopressin antagonists and oxytocin antagonists |
| JP2869854B2 (ja) | 1994-10-19 | 1999-03-10 | 株式会社トスカ | 合成樹脂の成形方法とその装置 |
| JP3534903B2 (ja) | 1995-06-09 | 2004-06-07 | 鐘淵化学工業株式会社 | １−［３−クロロ−（２ｓ）−メチルプロピオニル］−ピロリジン−（２ｓ）−カルボン酸の製造方法 |
| GB9603699D0 (en) * | 1996-02-21 | 1996-04-17 | Boots Co Plc | Therapeutic composition |
| US6696484B2 (en) * | 1997-10-31 | 2004-02-24 | University Of Chicago Office Of Technology And Intellectual Property | Method and compositions for regulation of 5-alpha reductase activity |
| US6329418B1 (en) | 1998-04-14 | 2001-12-11 | The Procter & Gamble Company | Substituted pyrrolidine hydroxamate metalloprotease inhibitors |
| US20030180352A1 (en) * | 1999-11-23 | 2003-09-25 | Patel Mahesh V. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| DE60027761T2 (de) * | 1999-12-09 | 2007-01-25 | Reckitt Benckiser Healthcare (Uk) Ltd., Slough | Komprimierte zubereitung enthaltend nichtsteroidale entzündungshemmer |
| ES2261404T3 (es) | 2000-03-27 | 2006-11-16 | Applied Research Systems Ars Holding N.V. | Derivados de pirrolidina utiles como inhibidores de bax. |
| DK1268418T3 (da) | 2000-03-27 | 2006-09-25 | Applied Research Systems | Farmaceutisk aktive pyrrolidinderivater som Bax-inhibitorer |
| IL157995A0 (en) | 2001-03-20 | 2004-03-28 | Applied Research Systems | The use of pyrrolidine ester derivatives in modulation of oxytoxin activity, some new such derivatives, their preparation and pharmaceutical compositions containing them |
| EP1444225B1 (en) | 2001-06-18 | 2012-10-10 | Merck Serono SA | Pyrrolidine oxadiazole- and thiadiazole oxime derivatives being oxytocin receptor antagonists. |
| JP2003192582A (ja) * | 2001-12-12 | 2003-07-09 | Merck Patent Gmbh | ナプロキセンナトリウムを含む速放性錠剤 |
| UA78058C2 (en) | 2002-07-05 | 2007-02-15 | Applied Research Systems | Pyrrolidine derivative as oxitocin antagonists |
| ES2333719T3 (es) | 2003-02-27 | 2010-02-26 | Merck Serono Sa | Derivados de pirrolidina en calidad de antagonistas de oxitocina. |
| EA011026B1 (ru) | 2004-02-26 | 2008-12-30 | Лаборатуар Сероно Са | Способ получения пирролидиноксимов |
| GB2411355B (en) * | 2004-02-27 | 2006-02-22 | Niche Generics Ltd | Pharmaceutical composition |
| KR100985449B1 (ko) * | 2005-05-10 | 2010-10-05 | 페링 인터내셔널 센터 에스 에이 | 옥시톡신 및/또는 바소프레신 길항제의 용도 |
| WO2007052289A2 (en) * | 2005-07-22 | 2007-05-10 | Rubicon Research Pvt Ltd. | Novel dispersible tablet composition |
| EP1978939A2 (en) * | 2005-12-27 | 2008-10-15 | Jubilant Organosys Limited | Mouth dissolving pharmaceutical composition and process for preparing the same using a high amount of silicon dioxine |
| JP2008189732A (ja) | 2007-02-01 | 2008-08-21 | Fujifilm Corp | セルロースアシレート組成物、セルロースアシレートフィルム、光学補償シート、偏光板および液晶表示装置 |
| US20090152770A1 (en) | 2007-08-07 | 2009-06-18 | Canon Virginia Inc. | Mechanically collapsible core for injection molding |
| PT2572705T (pt) * | 2007-10-01 | 2017-11-08 | Lesvi Laboratorios Sl | Comprimidos orodispersíveis |
| US9201077B2 (en) | 2009-07-27 | 2015-12-01 | Colorado State University Research Foundation | Direct enzyme immunoassay for measurement of serum progesterone levels |
| HK1213454A1 (zh) | 2012-11-26 | 2016-07-08 | Ferring B.V. | 使用图像分析诊断子宫收缩水平的方法和系统 |
| JP5942815B2 (ja) | 2012-11-26 | 2016-06-29 | 株式会社ジェイテクト | 等速ジョイント用ブーツの成形金型 |
| EP2845850A1 (en) | 2013-09-10 | 2015-03-11 | ObsEva S.A. | Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists |
| EP2886107A1 (en) * | 2013-12-17 | 2015-06-24 | ObsEva S.A. | Oral formulations of pyrrolydine derivatives |
| EP3753921A1 (en) | 2014-07-02 | 2020-12-23 | ObsEva S.A. | Crystalline (3z,5s)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one o-methyloxime useful in methods of treating conditions related to the ot-r activity |
| PL3037101T3 (pl) | 2014-12-22 | 2019-06-28 | Ferring B.V. | Terapia antagonistą receptora oksytocyny w fazie lutealnej w celu implantacji i uzyskania ciąży u kobiet poddawanych technikom wspomaganego rozrodu |
-
2013
- 2013-12-17 EP EP13197606.0A patent/EP2886107A1/en not_active Withdrawn
-
2014
- 2014-12-15 EA EA201691061A patent/EA031530B1/ru unknown
- 2014-12-15 CA CA2931592A patent/CA2931592C/en active Active
- 2014-12-15 JP JP2016534249A patent/JP6479800B2/ja active Active
- 2014-12-15 DK DK14820814.3T patent/DK3082773T3/en active
- 2014-12-15 WO PCT/EP2014/077767 patent/WO2015091365A1/en not_active Ceased
- 2014-12-15 ES ES14820814.3T patent/ES2654927T3/es active Active
- 2014-12-15 EP EP14820814.3A patent/EP3082773B1/en active Active
- 2014-12-15 CN CN201910736559.3A patent/CN110960495B/zh active Active
- 2014-12-15 MX MX2016007930A patent/MX363697B/es unknown
- 2014-12-15 PT PT148208143T patent/PT3082773T/pt unknown
- 2014-12-15 EA EA201892033A patent/EA201892033A3/ru unknown
- 2014-12-15 HU HUE14820814A patent/HUE035212T2/en unknown
- 2014-12-15 ES ES17188131T patent/ES2726730T3/es active Active
- 2014-12-15 US US15/104,683 patent/US20170065556A1/en not_active Abandoned
- 2014-12-15 UA UAA201606432A patent/UA116824C2/uk unknown
- 2014-12-15 SI SI201430538T patent/SI3082773T1/en unknown
- 2014-12-15 EP EP19150037.0A patent/EP3494967A1/en active Pending
- 2014-12-15 CN CN201480075770.0A patent/CN106029057B/zh active Active
- 2014-12-15 AU AU2014364962A patent/AU2014364962B2/en active Active
- 2014-12-15 EP EP17188131.1A patent/EP3266449B1/en active Active
- 2014-12-15 KR KR1020167018856A patent/KR102350156B1/ko active Active
- 2014-12-16 US US14/571,615 patent/US9962367B2/en active Active
-
2016
- 2016-05-25 IL IL245855A patent/IL245855B/en active IP Right Grant
- 2016-06-16 MX MX2019003598A patent/MX2019003598A/es unknown
-
2017
- 2017-12-28 CY CY20171101354T patent/CY1119728T1/el unknown
-
2018
- 2018-04-13 US US15/952,934 patent/US10478420B2/en active Active
- 2018-07-09 HK HK18108881.5A patent/HK1249050B/en unknown
-
2019
- 2019-01-15 IL IL264259A patent/IL264259A/en unknown
- 2019-02-06 JP JP2019019345A patent/JP2019108336A/ja active Pending
- 2019-09-12 US US16/569,065 patent/US11419851B2/en active Active
-
2022
- 2022-08-22 US US17/892,833 patent/US20230226021A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108938583B (zh) | 包含无定形达格列净的制剂 | |
| HRP20250257T1 (hr) | Farmaceutska kombinacija, pripravak i kombinirana priprema koja sadrži aktivator glukokinaze i inhibitor sglt-2 te metode pripreme i njihova uporaba | |
| US20090018175A1 (en) | Pharmaceutical excipient complex | |
| TWI788702B (zh) | {[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基}乙酸之固體型式，其組合物及用途 | |
| JP2007518760A5 (OSRAM) | ||
| JPWO2008072532A1 (ja) | 貯蔵安定性が改善された医薬組成物 | |
| JP7482182B2 (ja) | プロトンポンプ阻害剤を含む経口用固形製剤組成物、それを含む経口用固形製剤及びその製造方法 | |
| CN104661649A (zh) | 包含替格瑞洛的固态口服医药制剂 | |
| KR101910902B1 (ko) | 암로디핀, 로자탄 및 클로르탈리돈을 포함하는 약제학적 복합제제 | |
| CN107595788B (zh) | 一种用于口服固体制剂的复合崩解剂体系及含有该复合崩解剂体系的口服固体制剂 | |
| WO2014060545A1 (en) | Pharmaceutical compositions of dabigatran free base | |
| JP2013544272A5 (OSRAM) | ||
| CN104971355A (zh) | 含有利伐沙班的组合物及其制备方法 | |
| JP7641098B2 (ja) | リバーロキサバン含有錠剤 | |
| TW202200123A (zh) | 一種複合物的藥物組合物及其製備方法 | |
| CN102451171B (zh) | 替硝唑阴道泡腾片及其制备方法 | |
| JP2010535212A (ja) | 改良されたカンデサルタンの製剤 | |
| JP2009519985A5 (OSRAM) | ||
| KR20140043517A (ko) | 안정성이 개선된 칸데사르탄 실렉세틸을 함유하는 약제학적 조성물 및 이의 제조방법 | |
| WO2011081118A1 (ja) | 経口投与用医薬組成物 | |
| JP2015189677A (ja) | ソリフェナシン非晶質体を含有する医薬組成物 | |
| RU2281772C1 (ru) | Лекарственная форма, обладающая антиангинальным действием, и способ ее изготовления | |
| JPH11349475A (ja) | 口腔内崩壊錠及びその製造法 | |
| KR101524264B1 (ko) | 발사르탄 함유 경구용 약학 조성물 | |
| JP2012162467A (ja) | カンデサルタンシレキセチル含有造粒物の製造方法及びカンデサルタンシレキセチル含有錠剤の製造方法 |